# A comprehensive review of management modalities for glaucoma and intraocular hypertension during pregnancy

**Authors:** Nicoleta Anton, Francesca Cristiana Dohotariu, Theodora Armeanu, Răzvan Lisă, Camelia Margareta Bogdănici, Bogdan Doroftei

PMC · DOI: 10.1007/s10792-026-04030-w · International Ophthalmology · 2026-03-25

## TL;DR

This review explores how to manage glaucoma and high eye pressure during pregnancy, balancing maternal eye health with fetal safety.

## Contribution

The paper provides a comprehensive synthesis of current evidence on glaucoma management during pregnancy, including emerging minimally invasive surgical options.

## Key findings

- Pregnancy can cause intraocular pressure fluctuations influenced by factors like age, parity, and corneal thickness.
- Beta-blockers are commonly used, but punctal occlusion is advised to minimize systemic absorption.
- Minimally invasive glaucoma surgeries and laser treatments are emerging as viable options during pregnancy.

## Abstract

Glaucoma during pregnancy presents a complex clinical challenge, requiring a careful balance between effective intraocular pressure (IOP) control and fetal safety.

This review examines the ocular changes that occur during pregnancy and their implications for glaucoma progression and management.

It synthesizes current evidence on IOP fluctuations, disease progression risks, and the safety profiles of pharmacologic, laser, and surgical interventions. Studies were included if they met the following criteria: (1) involved pregnant women diagnosed with glaucoma or ocular hypertension; (2) evaluated medical, laser, or surgical management strategies during pregnancy; and (3) reported outcomes related to intraocular pressure control, optic nerve evaluation, or visual field assessment. Studies focusing exclusively on other ocular complications of pregnancy were excluded. Particular attention is given to emerging trends in minimally invasive glaucoma surgeries (MIGS), diagnostic innovations, and pharmacotherapies tailored to the gestational period. The PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) framework was used to guide methodological rigor and transparency.

From 257 initially identified records, 184 studies remained after duplicate removal. Following the title and abstract screening, 73 full text articles were assessed for eligibility. Ultimately, 54 studies met all inclusion criteria and were included in the final review. However, pregnancy introduces diagnostic challenges related to IOP assessment, variability in individual responses, and the possibility of paradoxical IOP elevation. The extent of IOP reduction during pregnancy may be influenced by physiological and demographic factors such as age, parity, systemic blood pressure, and central corneal thickness (CCT), all of which can modulate the degree of IOP change. For instance, multiparous women often exhibit greater IOP decreases than primigravidas. Beta-blockers remain among the most frequently prescribed agents during pregnancy; however, punctal occlusion is recommended to reduce systemic absorption. Alternative treatment options, including selective laser trabeculoplasty (SLT) and minimally invasive glaucoma surgery (MIGS), may be considered based on disease severity and gestational stage.

The findings advocate for a patient-centered approach that integrates evidence-based strategies to preserve maternal vision while ensuring fetal well-being. Ongoing research and interdisciplinary collaboration will be essential in developing new approaches while safeguarding both maternal and fetal health.

## Linked entities

- **Diseases:** glaucoma (MONDO:0005041)

## Full-text entities

- **Diseases:** renal disorder (MESH:D007674), congenital and infantile glaucoma (MESH:C565547), iridocorneal endothelial [ICE] syndrome (MESH:D057129), pigment dispersion syndromes (MESH:C563184), vision loss (MESH:D014786), corneal ectatic disorders (MESH:D003316), fibrosis (MESH:D005355), functional (MESH:D003291), visual field defects (MESH:D005128), punctal (OMIM:614187), maternal toxicity (MESH:D000079262), dry eye syndrome (MESH:D015352), anterior segment dysgenesis (MESH:C537775), SLT (MESH:D009155), glaucomatous optic neuropathy (MESH:D009901), fetal skeletal abnormalities (MESH:D005315), IOP (MESH:D064090), diabetic retinopathy (MESH:D003930), optic nerve damage (MESH:D020221), ocular trauma (MESH:D014947), ocular damage (MESH:D015817), paresthesia (MESH:D010292), metabolic (MESH:D008659), Axenfeld-Rieger syndrome (MESH:C535679), bleb leaks (MESH:D001768), dry mouth (MESH:D014987), Preeclampsia (MESH:D011225), vascular dysregulation (MESH:D021081), Glaucoma (MESH:D005901), vascular dysfunction (MESH:D002561), heart block (MESH:D006327), pseudoexfoliation (MESH:D017889), punctal occlusion (MESH:D001157), Sturge-Weber syndrome (MESH:D013341), JOAG (MESH:D005902), ocular hypertension (MESH:D009798), fetal malformations (MESH:D000013), preterm labor (MESH:D007752), abortion (MESH:D000026), gestational hypertension (MESH:D046110), MICS (MESH:D003229), blood dyscrasia (MESH:D006402), inflammation (MESH:D007249), gestational glaucoma (MESH:D016640), Anxiety (MESH:D001007), diabetes mellitus (MESH:D003920), central nervous system depression (MESH:D016543), respiratory depression (MESH:D012131), chronic obstructive pulmonary disease (MESH:D029424), gastrointestinal disturbances (MESH:D005767), PACG (MESH:D015812), tachyarrhythmias (MESH:D013610), hypertensive retinopathy (MESH:D058437), fatigue (MESH:D005221), neuroinflammatory (MESH:D000090862), ocular surface irritation (MESH:D001523), emphysema (MESH:D004646), uveitis (MESH:D014605), teratogenic (MESH:C535542), complications (MESH:D008107)
- **Chemicals:** benzalkonium chloride (MESH:D001548), Durysta (MESH:D000069580), prostaglandin analogues (MESH:D011465), C (MESH:D002244), etidocaine (MESH:D005041), MICS (-), Netarsudil (MESH:C000603944), Lidocaine (MESH:D008012), Brimonidine (MESH:D000068438), nitric oxide (MESH:D009569), Prostaglandin (MESH:D011453), MMC (MESH:D016685), prilocaine (MESH:D011318), isosorbide (MESH:D007547), urea (MESH:D014508), mannitol (MESH:D008353), glycerol (MESH:D005990), water (MESH:D014867), timolol (MESH:D013999), Bupivacaine (MESH:D002045), 5-FU (MESH:D005472), Allergan (MESH:C004664), pilocarpine (MESH:D010862), acetazolamide (MESH:D000086), Progesterone (MESH:D011374), mepivacaine (MESH:D008619), dorzolamide (MESH:C062765), Apraclonidine (MESH:C016986)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116], Oryctolagus cuniculus (domestic rabbit, species) [taxon 9986], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13017985/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC13017985/full.md

---
Source: https://tomesphere.com/paper/PMC13017985